---
title: "Setmelanotide"
canonical_url: https://peptidelibrary.app/library/setmelanotide
description: "FDA-approved MC4R agonist (Imcivree) for rare genetic obesities (POMC, PCSK1, LEPR deficiency, Bardet-Biedl). Daily SC injection, not a general-obesity drug."
updated: 2026-09-06
publisher: Peptide Library
notice: "Research and educational use only. Not medical advice."
---

# Setmelanotide

Setmelanotide (also called Imcivree or RM-493) is an FDA-approved MC4R agonist. Setmelanotide is a cyclic peptide agonist selective for the melanocortin-4 receptor. MC4R sits at the bottom of the leptin-melanocortin pathway: leptin signals adiposity to the hypothalamus, POMC neurons release alpha-MSH, and alpha-MSH acts at MC4R to suppress appetite.

FDA-approved MC4R agonist (Imcivree) for rare genetic obesities (POMC, PCSK1, LEPR deficiency, Bardet-Biedl). Daily SC injection, not a general-obesity drug.

Also known as: Imcivree, RM-493, MC4R agonist.

Categories: Fat Loss, GLP-1/Metabolic.

## Classification

- Type: FDA-approved MC4R agonist
- Mechanism class: MC4R agonist
- Development stage: Approved product
- Regulatory class: FDA-approved medicine

## Mechanism

Setmelanotide is a cyclic peptide agonist selective for the melanocortin-4 receptor. MC4R sits at the bottom of the leptin-melanocortin pathway: leptin signals adiposity to the hypothalamus, POMC neurons release alpha-MSH, and alpha-MSH acts at MC4R to suppress appetite. In monogenic obesities caused by loss-of-function variants upstream of the receptor — in POMC, PCSK1 or the leptin receptor — that signal never arrives, but MC4R itself remains intact and responsive. Setmelanotide restores the missing signal by activating the receptor directly. It therefore works only where the defect lies upstream, which is why its approved use is defined by genetic diagnosis rather than by obesity itself.

Targets: MC4R.

Origin: Synthetic cyclic peptide MC4R agonist.

## Properties

- Molecular formula: C49H68N18O9S2
- Molecular weight: 1,117.3 g/mol
- CAS number: 920014-72-8
- Half-life: ~11 hours
- Studied routes: Subcutaneous

## Evidence

- Evidence level: FDA Approved
- Highest documented: Regulatory review (FDA label)
- Human trials: 3
- Controlled human trials: 3
- Preclinical sources: 0
- Latest source: 2026

Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.

### Studies

1. IMCIVREE (setmelanotide) injection — FDA prescribing information, DailyMed. Regulatory label (FDA), human. Population: Patients aged 4+ with acquired hypothalamic obesity; aged 2+ with Bardet-Biedl syndrome; aged 2+ with confirmed POMC, PCSK1 or LEPR variants. Reduction of excess body weight [Source](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=70c3ccf7-4df0-4c75-ba07-fede9970c8d9)
2. Setmelanotide for the Treatment of Acquired Hypothalamic Obesity. N Engl J Med. 2026. 2026. Controlled human trial. Population: Patients with acquired hypothalamic obesity. Body mass index reduction [Source](https://pubmed.ncbi.nlm.nih.gov/42418774/)
3. NCT03746522 — Setmelanotide (RM-493), MC4R Agonist, in Bardet-Biedl Syndrome. Controlled human trial. Population: Patients with Bardet-Biedl syndrome (n=52). Weight and hunger scores [Source](https://clinicaltrials.gov/study/NCT03746522)
4. NCT03287960 — Setmelanotide for the Treatment of Leptin Receptor (LEPR) Deficiency Obesity. Controlled human trial. Population: Patients with leptin receptor deficiency obesity (n=15). Weight reduction [Source](https://clinicaltrials.gov/study/NCT03287960)

### Registered trials

- [NCT03746522](https://clinicaltrials.gov/study/NCT03746522)
- [NCT03287960](https://clinicaltrials.gov/study/NCT03287960)

## Safety

Side effects: Hyperpigmentation; Nausea; Sexual-arousal disturbances; Injection reactions.

Risks: Depression/suicidal-ideation monitoring; Not for common obesity.

Human safety basis: FDA prescribing information

## Regulatory status

Setmelanotide is an FDA-approved product for specific labelled indications. Approval does not extend to the research contexts described on this page, and approved products are prescription medicines.

- FDA status: Approved
- WADA status: Permitted
- Availability: Prescription-Only

## Frequently asked questions

### What is Setmelanotide?

FDA-approved MC4R agonist (Imcivree) for rare genetic obesities (POMC, PCSK1, LEPR deficiency, Bardet-Biedl). Daily SC injection, not a general-obesity drug.

### How does Setmelanotide work?

Setmelanotide is a cyclic peptide agonist selective for the melanocortin-4 receptor. MC4R sits at the bottom of the leptin-melanocortin pathway: leptin signals adiposity to the hypothalamus, POMC neurons release alpha-MSH, and alpha-MSH acts at MC4R to suppress appetite.

### Is Setmelanotide FDA approved?

Yes. Setmelanotide is approved by the FDA, and approved products are prescription medicines. Approval is always for specific indications studied in clinical trials, so an approved status does not mean the compound is approved for every use it is discussed for. Research-chemical material sold under the same name is not the approved product.

### What is the half-life of Setmelanotide?

Reported half-life for Setmelanotide is ~11 hours. Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.

### Is Setmelanotide banned in sport?

Setmelanotide is recorded here as permitted in sport. Anti-doping status is revised annually, so athletes subject to testing should confirm against the current WADA Prohibited List before use.

### What peptides are similar to Setmelanotide?

Compounds most often compared with Setmelanotide include Melanotan II, Afamelanotide, Bremelanotide and KPV. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.

## References

- [FDA label — Imcivree](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213793s005lbl.pdf)
- [Setmelanotide for the Treatment of Acquired Hypothalamic Obesity — N Engl J Med, 2026](https://pubmed.ncbi.nlm.nih.gov/42418774/)
- [Could setmelanotide be the game-changer for acquired hypothalamic obesity? — Front Endocrinol (Lausanne), 2023](https://pubmed.ncbi.nlm.nih.gov/38239988/)
- [Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alström syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label period — Lancet Diabetes Endocrinol, 2022](https://pubmed.ncbi.nlm.nih.gov/36356613/)
- [Setmelanotide for the treatment of acquired hypothalamic obesity: a phase 2, open-label, multicentre trial — Lancet Diabetes Endocrinol, 2024](https://pubmed.ncbi.nlm.nih.gov/38697184/)
- [Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials — Lancet Diabetes Endocrinol, 2020](https://pubmed.ncbi.nlm.nih.gov/33137293/)
